Development of attenuated coxsackievirus B3 vectored intranasal pre-emptive pan-coronavirus vaccine
Deng, H.; He, X.; Li, Y.; Wang, H.; Wang, S.; Gu, L.; Zhang, H.; Zhu, J.; Li, R.; Wang, G.
Show abstract
SARS-CoV-2 has the ability to evade immunity, resulting in breakthrough infections even after vaccination. Similarly, zoonotic coronaviruses pose a risk of spillover to humans. There is an urgent need to develop a pre-emptive pan-coronavirus vaccine that can induce systemic and mucosal immunity. Here, we employed a combination of immune-informatics approaches to identify shared immunodominant linear B- and T-cell epitopes from SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs), as well as zoonotic coronaviruses. Epitope-guided vaccine were designed and the attenuated coxsackievirus B3 vectored intranasal vaccines rCVB3-EPI and rCVB3-RBD-trimer were constructed. The immunogenicity of these candidate vaccines was evaluated using Balb/c mice. The results demonstrated effective immune responses, including the production of SARS-CoV-2-specific IgG and sIgA antibodies, as well as T cell-mediated responses. However, further verification is required to assess cross-reactivity with various variants. Our intranasal pre-emptive pan-coronavirus vaccine design framework offers an appealing candidate for future vaccine development.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants 95%
- Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial 94%
- Robust Neutralization of SARS-CoV-2 Variants Including JN.1 and BA.2.87.1 by Trivalent XBB Vaccine-Induced Antibodies 94%
Similar papers in this journal
- One year landscape of the inactivated virus vaccine triggered RBD-specific IgG, IgM and IgA responses against the Omicron variant 97%
- Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD 96%
- Enhanced neutralization against SARS-CoV-2 by vaccine booster exhibits reduction of Omicron variant 95%
Similar papers in this journal
Similar papers in this journal
- Long-term Immunity of a Microneedle Array Patch of SARS-CoV-2 S1 Protein Subunit Vaccine Irradiated by Gamma Rays in Mice 96%
- Oral immunization with rVSV bivalent vaccine elicits protective immune responses, including ADCC, against both SARS-CoV-2 and Influenza A viruses 96%
- Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2 95%
Similar papers in this journal
- Prime-boost vaccination of mice and Rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates 97%
- Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques 96%
- Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.